- 3 Top Dividend Stocks to Maximize Your Retirement Income
May 11, 2026
Here's a revealing data point: older Americans are scared more of outliving wealth than of death itself.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved for their golden years. That\s because the traditional ways people manage retirement may no longer provide enough income to meet expenses- and with people generally living longer, the principal retirement savings is exhausted far too early in the retirement period.
Retirement investing approaches of the past don't work today.
Years ago, investors at or close to retirement could put money into fixed-income assets and depend on appealing yields to generate consistent, solid pay streams to fund a comfortable retirement. 10-year Treasury bond rates in the late 1990s floated around 6.50%, but unfortunately, those days of being able to exclusively rely on Treasury yields to fund retirement income are over.
While this yield reduction may not seem drastic, it adds up: for a $1 million investment in 10-year Treasuries, the rate drop means a difference in yield of more than $1 million.
In addition to the considerable drop in bond yields, today's retirees are nervous about their future Social Security benefits. Because of certain demographic factors, it's been estimated that the funds that pay the Social Security benefits will run out of money in 2035.
So what's a retiree to do? You could cut your expenses to the bone, and take the risk that your Social Security checks don't shrink. Or you could find an alternative investment that provides a steady, higher-rate income stream to replace dwindling bond yields.
Invest in Dividend Stocks
Dividend-paying stocks from low-risk, high-quality companies are a smart way to generate steady and reliable attractive income streams to replace low risk, low yielding Treasury and bond options.
Look for stocks that have paid steady, increasing dividends for years (or decades), and have not cut their dividends even during recessions.
A rule of thumb for finding solid income-producing stocks is to seek those that average 3% dividend yield, and positive yearly dividend growth. These stocks can help combat inflation by boosting dividends over time.
Here are three dividend-paying stocks retirees should consider for their nest egg portfolio.
Amgen (AMGN) is currently shelling out a dividend of $2.52 per share, with a dividend yield of 3.04%. This compares to the Medical - Biomedical and Genetics industry's yield of 0% and the S&P 500's yield of 1.41%. The company's annualized dividend growth in the past year was 5.78%. Check Amgen dividend history here>>>
Story Continues
Bar Harbor Bankshares (BHB) is paying out a dividend of $0.34 per share at the moment, with a dividend yield of 3.66% compared to the Banks - Northeast industry's yield of 2.17% and the S&P 500's yield. The annualized dividend growth of the company was 6.67% over the past year. Check Bar Harbor Bankshares dividend history here>>>
Currently paying a dividend of $0.31 per share, Brixmor Property (BRX) has a dividend yield of 4.12%. This is compared to the REIT and Equity Trust - Retail industry's yield of 3.89% and the S&P 500's current yield. Annualized dividend growth for the company in the past year was 5.5%. Check Brixmor Property dividend history here>>>
But aren't stocks generally more risky than bonds?
It is true that stocks, as an asset class, carry more risk than bonds, but high-quality dividend stocks not only have the ability to produce income growth over time but more importantly, can also reduce your overall portfolio volatility relative to the broader stock market.
An advantage of owning dividend stocks for your retirement nest egg is that numerous companies, particularly blue chip stocks, raise their dividends over time, helping alleviate the impact of inflation on your potential retirement income.
Thinking about dividend-focused mutual funds or ETFs? Watch out for fees.
You may be thinking, "I like this dividend strategy, but instead of investing in individual stocks, I'm going to find a dividend-focused mutual fund or ETF." This approach can make sense, but be aware that some mutual funds and specialized ETFs carry high fees, which may reduce your dividend gains or income, and defeat the goal of this dividend investment approach. If you do wish to invest in a fund, do your research to find the best-quality dividend funds with the lowest fees.
Bottom Line
Whether you select high-quality, low-fee funds or stocks, seeking the steady income of dividend-paying equities can potentially offer you a path to a better and more stress-free retirement.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- The Next Generation of the GLP-1 Revolution Is Already Underway
May 11, 2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).
As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine. SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.
Click here to view the custom infographic of the SureNano Science editorial.
GLP-1 Therapies Reshape Global Healthcare
The global obesity crisis continues to intensify. According to the World Health Organization, an estimated one billion people worldwide are living with obesity, while rates of type 2 diabetes continue to rise across both developed and emerging economies. The WHO further notes that obesity significantly increases the risk of cardiovascular disease, stroke and type 2 diabetes, while additional research has linked excess weight to chronic kidney disease and rising healthcare expenditures, creating substantial pressure on healthcare systems globally.
GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine. Originally developed for blood glucose regulation in diabetes patients, these therapies are now widely recognized for their ability to produce meaningful weight loss and improve broader metabolic outcomes. Industry leaders Novo Nordisk A/S and Eli Lilly and Company currently dominate the market through blockbuster injectable products including Ozempic(R), Wegovy(R), Mounjaro(R) and Zepbound(R).
Commercial expectations surrounding this sector continue to accelerate. JPMorgan Chase & Co. projects the broader obesity drug market could approach $200 billion by 2030 as adoption expands globally and indications broaden beyond diabetes and weight management. Additional industry forecasts suggest GLP-1 therapies could become one of the most commercially successful pharmaceutical categories in history, with annual sales projections reaching $150 billion or more by the end of the decade.
At the same time, the industry is already shifting toward next-generation incretin therapies focused on improving efficacy, tolerability and convenience. Oral formulations, expanded indications and combination metabolic therapies are becoming major priorities across the pharmaceutical sector. Within this evolving landscape, SureNano Science is positioning itself as an agile entrant pursuing differentiated innovation through GEP-44, a patented triple agonist peptide licensed from Syracuse University and designed to advance through the U.S. Food and Drug Administration (FDA) regulatory pathway.
A Differentiated Next-Generation GLP Candidate
SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA pathway. Unlike conventional GLP-1 agonists that primarily target a single receptor pathway, GEP-44 functions as a triple agonist targeting GLP-1 and peptide YY receptors Y1 and Y2. This integrated mechanism is designed to simultaneously regulate glucose metabolism, suppress appetite and improve tolerability within a single molecule.
The compound was developed at Syracuse University and has demonstrated encouraging preclinical results. According to the company, GEP-44 produced meaningful reductions in food intake and body weight while also improving glycemic control in preclinical studies. Importantly, the compound reportedly avoided the nausea and gastrointestinal side effects commonly associated with many first-generation GLP-1 therapies, a factor that could become increasingly important as patient adoption expands.
The broader pharmaceutical industry is aggressively pursuing differentiated incretin therapies capable of addressing patient tolerability and adherence challenges. PwC notes that the next phase of the obesity drug market will likely be defined by expanded indications, improved delivery methods and therapies offering better long-term patient adherence. This creates a favorable backdrop for companies pursuing second-generation GLP innovation.
While smaller than major pharmaceutical incumbents, SureNano Science operates with a lean development structure and cost-efficient strategy designed to maximize flexibility and accelerate development timelines. The company conducts significant research activities in Australia, where government incentives may provide research tax credits of up to 43.5% on eligible expenditures. If GEP-44 continues to demonstrate positive outcomes through future clinical development, the company could position itself as a potential acquisition, licensing or partnership candidate within the rapidly expanding GLP ecosystem.
Positioned Within Massive Market Expansion
The commercial opportunity surrounding GLP-1 therapies continues to grow rapidly. According to Morgan Stanley, the global GLP-1 market could approach $190 billion by 2035 as patient adoption expands and broader therapeutic applications emerge. Industry forecasts from BCC Research similarly projects substantial long-term growth — $268.4 billion by 2030 — in the GLP-1 analogue market through the end of the decade.
Patient adoption is also accelerating. Estimates suggest that anywhere from 25 to 30 million Americans could be using GLP-1 therapies by 2030, compared with approximately 10 million users in 2026. Expanding insurance coverage, rising obesity prevalence and broader physician adoption are all contributing to the rapid mainstream acceptance of these therapies.
The competitive landscape is simultaneously evolving toward next-generation products. IQVIA describes 2026 as potentially becoming the “year of the orals,” with oral GLP-1 formulations expected to significantly improve accessibility, adherence and long-term maintenance therapy adoption. Off-patent semaglutide expansion across major global markets is also expected to increase competition and broaden overall patient access.
As GEP-44 advances through IND-enabling studies and toward eventual phase I trials, SureNano Science represents one of the relatively few microcap public companies providing direct exposure to the rapidly expanding GLP-1 market. This creates a potential valuation disconnect compared with large-cap pharmaceutical incumbents and later-stage obesity therapy developers, particularly if the company successfully achieves meaningful clinical and regulatory milestones.
Advanced Delivery Technologies Expand Opportunity
Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence. The company’s platform strategy includes evaluating oral, sublingual and intranasal delivery approaches that could eventually reduce dependence on injectable therapies.
Convenience and adherence are becoming increasingly important competitive factors within the GLP-1 market. Current market-leading therapies are primarily injectable, which can create barriers for some patients due to administration complexity, refrigeration requirements and long-term compliance challenges. Oral and noninvasive alternatives are widely viewed as one of the next major commercial opportunities within obesity and diabetes therapeutics.
Industry analysts increasingly believe delivery innovation could become just as important as efficacy itself. IQVIA notes that oral obesity therapies could dramatically improve long-term maintenance adoption while simplifying distribution logistics by eliminating cold-chain requirements. This could significantly expand patient accessibility across international markets.
By combining therapeutic development with delivery innovation, SureNano Science is building a vertically integrated metabolic disease platform rather than focusing solely on a single injectable drug candidate. This broader platform strategy may create additional long-term optionality and commercial flexibility as the obesity treatment market continues evolving.
Preclinical Results Highlight Competitive Potential
Preclinical data released by SureNano Science suggest that GEP-44 may offer meaningful differentiation compared with earlier-generation GLP therapies, positioning the company for meaningful upside as it progresses through its development phases of the FDA approval pathway. According to the company, the compound demonstrated approximately 15% weight loss in preclinical testing compared with roughly 9% observed with liraglutide, while food intake reductions approached 39% versus approximately 20% for the comparator.
In addition to weight reduction, GEP-44 also demonstrated improved glycemic control while reportedly avoiding nausea and vomiting during testing. Gastrointestinal side effects remain one of the most significant challenges associated with many currently marketed GLP-1 therapies and are a major factor affecting long-term patient adherence. Improved tolerability could therefore become an important competitive advantage if these findings translate successfully into clinical studies.
The pharmaceutical industry continues investing heavily into next-generation obesity therapies capable of improving efficacy and patient experience. The Pharma Letter reports that obesity drug pipelines are increasingly focused on differentiation through combination pathways, enhanced tolerability and expanded delivery approaches as competition intensifies.
While GEP-44 remains in preclinical development, these early findings position SureNano Science within a highly strategic segment of the obesity treatment landscape. If future studies continue validating these results, the company could emerge as a differentiated participant in one of the largest and fastest-growing therapeutic categories in modern healthcare.
Strategic Expansion Creates Future Optionality
In addition to advancing its core GLP-1 metabolic disease platform, SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio. These discussions include nonbinding opportunities involving ibogaine-related intellectual property focused on formulation and delivery technologies.
While still exploratory and not considered a core asset at this stage, the initiative reflects a broader strategy aimed at building diversified platform capabilities across multiple high-growth therapeutic areas. Interest in ibogaine and related psychedelic-based therapeutics has increased significantly in recent years as researchers investigate their potential applications in addiction treatment, mental health disorders and neurological conditions.
CNN recently reported growing scientific and regulatory attention surrounding ibogaine research, particularly in areas involving opioid addiction and treatment-resistant mental health conditions. At the same time, the U.S. Food and Drug Administration has signaled increasing interest in accelerating development pathways for treatments targeting serious mental illnesses and unmet medical needs.
SureNano’s interest in formulation and delivery technologies within these emerging areas aligns with the company’s broader emphasis on drug-delivery innovation and platform flexibility. Rather than positioning ibogaine-related opportunities as a standalone commercial focus, the company appears to be evaluating how specialized delivery technologies and intellectual property could complement its existing expertise in metabolic therapeutics and nontraditional administration approaches. This type of optionality may provide additional long-term strategic value if regulatory environments surrounding psychedelic-based therapies continue to evolve favorably.
These initiatives remain early stage and subject to substantial scientific, clinical and regulatory uncertainty. However, by evaluating selective expansion opportunities alongside its primary GLP-1 development efforts, SureNano Science is positioning itself within a broader trend toward diversified therapeutic platforms capable of addressing multiple large and evolving healthcare markets. As pharmaceutical innovation increasingly converges around metabolic health, neuroscience and advanced delivery technologies, strategic flexibility could become an increasingly valuable differentiator for emerging biotechnology companies.
GLP-1 Market Enters New Phase
The GLP-1 sector continues to evolve rapidly as pharmaceutical developers expand treatment options for obesity, diabetes and related metabolic conditions. Recent advancements across the space highlight growing momentum behind next-generation oral therapies, long-acting injectable formulations and reduced-frequency dosing approaches designed to improve patient convenience, broaden access and enhance long-term treatment outcomes in one of healthcare’s fastest-growing therapeutic markets.
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Foundayo(TM) (orforglipron) for adults with obesity or who are overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect(R), with prescriptions accepted immediately and shipping beginning April 6, followed shortly after with broad availability through U.S. retail pharmacies and telehealth providers.
Novo Nordisk A/S (NYSE: NVO) announced that Ozempic(R) (semaglutide) tablets 1.5 mg, 4 mg and 9 mg will be available for adults with type 2 diabetes in the United States. Ozempic is the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes indicated not only to improve blood sugar, along with diet and exercise, but also to reduce the risk of major cardiovascular events (MACE) such as heart attack, stroke or death in those who are also at high risk for these events.
Amgen Inc. (NASDAQ: AMGN) is reporting full results from part 1 of the phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to these data, complete results from the primary analysis of the phase 1 pharmacokinetics low-dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led symposium at the 85th American Diabetes Association (ADA) Scientific Sessions and simultaneously published in “TheNew England Journal of Medicine.”
Pfizer Inc. (NYSE: PFE) announced positive topline results from the phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives: to demonstrate PF’3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain its efficacy while reducing the dosing frequency four-fold and to demonstrate PF’3944 could switch to a four-fold equivalent monthly dose while maintaining a well-tolerated and favorable safety profile.
These key announcements underscore the continued transformation of the metabolic disease landscape, where innovation is increasingly focused on efficacy, accessibility and patient adherence. As competition intensifies and new formulations move through regulatory and clinical milestones, the GLP-1 market is poised to remain a major driver of growth and innovation across the broader pharmaceutical industry.
For more information, visit SureNano Science.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or republished: https://wwwBioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
- AMGN Fairly Valued by DCF at $292
May 11, 2026 · gurufocus.com
On May 11, 2026, we delve into the discounted cash flow (DCF) analysis for Amgen Inc (AMGN), a company that has shown a price performance of +25.8% over the pas
- Will FDA-Backed Real-Time Trials in SCLC Reframe Amgen's (AMGN) R&D Narrative?
May 10, 2026
The U.S. FDA recently highlighted Amgen’s role in its real‑time clinical trials initiative, confirming the initiation of Amgen’s Phase 1b STREAM-SCLC study in limited-stage small cell lung cancer using real-time data signal sharing. This positions Amgen at the forefront of emerging “continuous” trial frameworks that aim to shorten development timelines and could change how oncology drugs are tested and reviewed. We’ll now examine how Amgen’s early involvement in real-time oncology trials might influence its broader investment narrative and long-term R&D profile.
Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
Amgen Investment Narrative Recap
To own Amgen, you need to believe in its ability to refresh an aging portfolio with new biologics while managing pricing pressure, biosimilar competition, and rising R&D and manufacturing spend. The FDA’s real time clinical trial initiative and Amgen’s STREAM SCLC study are important for its long term oncology pipeline, but the more immediate catalysts and risks still center on execution in existing franchises, pricing headwinds, and whether heavier investment starts to weigh on margins.
The most relevant recent update here is Amgen’s 2026 guidance, which calls for total revenue of US$37.1 billion to US$38.5 billion and GAAP EPS of US$15.62 to US$17.10. Those numbers frame how much room Amgen has to absorb higher R&D and capital spending, including its growing U.S. manufacturing footprint, while it experiments with new trial models like real time oncology studies.
Yet, against this backdrop of innovation and capacity expansion, investors should also be aware that heavier, sustained R&D and manufacturing investment could pressure near term margins if late stage programs underperform or face delays...
Read the full narrative on Amgen (it's free!)
Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028. This requires 2.3% yearly revenue growth and an earnings increase of about $1.6 billion from $6.6 billion today.
Uncover how Amgen's forecasts yield a $350.03 fair value, a 6% upside to its current price.
Exploring Other PerspectivesAMGN 1-Year Stock Price Chart
Some of the lowest estimate analysts were already assuming flat revenue near US$36.7 billion and slightly shrinking margins, which is a far more pessimistic view than the consensus. As you look at Amgen’s real time trials and manufacturing build out, it is worth weighing how these new developments might challenge that bearish case or reinforce concerns about returns on all this spending.
Story Continues
Explore 4 other fair value estimates on Amgen - why the stock might be worth just $350.03!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.
Want Some Alternatives?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMGN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Amgen’s Real Time FDA Trial Pilot Puts Oncology Execution In Focus
May 10, 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Amgen (NasdaqGS:AMGN) has been selected by the US Food and Drug Administration to participate in its real time clinical trials initiative. The company will apply the framework to its Phase 1b STREAM SCLC trial in small cell lung carcinoma. The initiative enables the FDA to receive trial data signals in real time, with the goal of improving trial efficiency and drug development timelines.
Amgen focuses on biotechnology driven therapies, including oncology, where clinical trial design and speed of evidence generation are increasingly important. Real time data sharing for the STREAM SCLC trial fits into a broader push across drug development to use digital tools and more flexible protocols to assess safety and efficacy signals sooner.
For investors watching NasdaqGS:AMGN, participation in the FDA's real time clinical trials initiative reflects how the company is approaching complex oncology programs. The results, when available, may inform how regulators and large biopharma companies run future studies in small cell lung carcinoma and other cancer indications.
Stay updated on the most important news stories for Amgen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amgen.NasdaqGS:AMGN Earnings & Revenue Growth as at May 2026
📰 Beyond the headline: 1 risk and 3 things going right for Amgen that every investor should see.
For you as an investor, Amgen’s role in the FDA’s real time clinical trials initiative is primarily about execution quality rather than immediate financial impact. Real time signal sharing in the Phase 1b STREAM SCLC study could shorten decision cycles, help identify safety or efficacy trends earlier and reduce the risk of spending heavily on trials that later need redesign. In oncology, where peers such as Merck, Bristol Myers Squibb and AstraZeneca are also active, being able to design more adaptive, data rich studies can be a differentiator in how quickly a company moves from early trials toward larger programs and, eventually, commercial opportunities.
How This Fits Into The Amgen Narrative
The focus on real time clinical data fits with the narrative around digital transformation and AI driven workflows supporting productivity across R&D and potentially helping Amgen bring targeted therapies to market more efficiently. At the same time, using more complex trial frameworks could increase near term R&D intensity, which links back to the narrative risk that heavy late stage investment may pressure margins and cash flow if programs do not deliver. The specific operational lessons from running a real time trial in small cell lung carcinoma are not explicitly captured in the broader narrative about chronic diseases and biosimilars, so investors may want to watch how management references this pilot in future commentary.
Story Continues
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Amgen to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Real time clinical trials could require higher upfront spending on data infrastructure and trial oversight, which matters given analysts have flagged that debt is not well covered by operating cash flow. ⚠️ If early signals in STREAM SCLC are not supportive, that could raise questions about parts of the oncology pipeline and the payback on increased R&D and capital expenditure. 🎁 Successful use of real time trials may improve the efficiency of early phase development and support the broader push into targeted oncology, which ties into expectations for earnings growth. 🎁 Participation in an FDA proof of concept program may help Amgen influence future regulatory expectations around continuous trials, potentially benefiting its broader portfolio versus smaller competitors.
What To Watch Going Forward
From here, focus on how often management refers to real time clinical trials in conference presentations and earnings calls, and whether they outline concrete benefits such as faster go or no go decisions or changes in trial timelines. It is also worth tracking how this approach is rolled out beyond STREAM SCLC into other oncology or rare disease programs, and whether regulators extend similar frameworks more widely across the sector. Any commentary on R&D spending, capital allocation and debt coverage will help you judge how these trial approaches fit alongside Amgen’s manufacturing expansions and pipeline priorities.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Amgen, head to the community page for Amgen to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMGN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Trump says unaware of a plan to fire FDA commissioner
May 9, 2026
Anna Moneymaker/Getty Images News
Amid multiple reports suggesting that President Donald Trump has signed off on a plan to oust FDA commissioner Marty Makary, Trump said late Friday that he is completely unaware of such a proposal.
The Wall Street Journal first reported Trump’s plans on Friday, noting that senior White House officials have become increasingly convinced that Makary, a former pancreatic surgeon at Johns Hopkins University, should depart after a tumultuous period leading the FDA. [https://seekingalpha.com/news/4590068-trump-to-fire-fda-commissioner-marty-makary-wsj]
Leaving the White House Friday evening, Trump dismissed the idea in response to a question from a reporter. “Are you going to fire him?” the reporter asked. “I’ve been reading about it, but I know nothing about it,” the President said.
Makary, nominated by Trump to lead the FDA in November 2024, has overseen an agency that has suffered several high-profile departures in recent months.
Richard Pazdur, the director of the FDA's Center for Drug Evaluation and Research and a 26-year veteran at the agency, sought retirement in December, just weeks after Makary picked him to lead the unit. [https://seekingalpha.com/news/4527734-fda-top-drugs-official-pazdur-retiring-shortly-after-starting]
Vinay Prasad, the former head of the FDA’s Center for Biologics Evaluation and Research, left the agency last month, marking his second departure in less than eight months.
MORE ON PHARMA MAJORS
* Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4898600-pfizer-inc-pfe-q1-2026-earnings-call-transcript]
* Pfizer Q1 Earnings Review: Stuck In Second Gear, But Dividend Helps [https://seekingalpha.com/article/4898517-pfizer-q1-earnings-review-stuck-in-second-gear-but-dividend-helps]
* Pfizer Inc. 2026 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4898522-pfizer-inc-2026-q1-results-earnings-call-presentation]
* HHS officials considered banning SSRI antidepressants - report [https://seekingalpha.com/news/4590187-hhs-officials-considered-banning-ssri-antidepressants-report]
* FDA food head eyed as acting commissioner - report [https://seekingalpha.com/news/4590184-fda-food-head-eyed-acting-commissioner-report]
- 2 Dividend Stocks to Double Up On Right Now
May 8, 2026
Equity markets have handled the economic uncertainty and geopolitical instability we have seen in recent months admirably well so far. The S&P 500 is up 7% year to date. However, we may not be completely out of the woods. Who knows what else will happen that may bring fresh concerns to Wall Street? One way to prepare for that is to invest in quality dividend stocks. They tend to have robust underlying businesses, and the regular income they provide can help smooth out market losses in challenging times. With that said, let's consider two attractive income stocks investors might want to consider right now: Amgen(NASDAQ: AMGN) and Merck(NYSE: MRK). Image source: The Motley Fool.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
1. Amgen
Last year, Amgen began facing biosimilar competition for denosumab, a medicine approved for osteoporosis (a bone disease), among other conditions. Although denosumab was a key growth driver for the biotech, its broad product lineup is helping it navigate this patent cliff fairly well. Amgen's revenue moved in the right direction last year and should do so again in 2026, based on the company's guidance.
Other products, including asthma treatment Tezspire and thyroid eye disease medicine Tepezza, are helping pick up the slack. In total, 16 of the company's brands posted double-digit growth during the first quarter. Amgen also has a deep pipeline with important potential catalysts over the next 18 months. One of the company's most promising candidates, MariTide, is an investigational GLP-1 medicine currently being evaluated in phase 3 studies in weight management and other indications.
MariTide is being developed as a once-monthly anti-obesity option -- none currently exists on the market. Provided it performs well in late-stage clinical trials, it could attract a significant number of patients in the fast-growing weight-loss niche.
Amgen has plenty of other phase 3 programs. The company is notably developing biosimilars for billion-dollar medicines, including Opdivo and Keytruda, two of the world's best-selling cancer drugs that will lose patent exclusivity within a few years. Amgen's biosimilar business is already performing pretty well, with its Pavblu (a biosimilar to Eylea) posting decent sales growth.
Amgen is well-positioned to deliver solid financial results for the foreseeable future, backed by its biosimilar business, a deep pipeline, and a strong lineup of medicines. Lastly, Amgen is a solid dividend stock. It has raised its payouts every year since initiating them in 2011, and it currently offers a forward yield of 3%, well above the S&P 500's average of 1.1%. Amgen is a great income-oriented stock pick to buy right now and hold onto for a long time.
Story Continues
2. Merck
Merck's most important medicine, Keytruda, will lose patent exclusivity in the U.S. in 2028. What will happen once biosimilars (like the one Amgen is developing) flood the market? The pharmaceutical giant is prepared to handle that. It has received approval for a subcutaneous version of Keytruda, which should capture some of the old version's patients since it is easier and faster to administer without compromising efficacy.
That alone won't be enough to fill Keytruda's big shoes, but Merck has plenty of other tricks up its sleeve. The company has expanded its pipeline in recent years, partly thanks to acquisitions. Some of the company's newer approvals have already been successful and will also help it move beyond Keytruda. For instance, Merck's Winrevair, a medicine for pulmonary arterial hypertension, is performing very well. The company's Capvaxive, a pneumonia vaccine, is also posting strong sales growth.
Merck has several more attractive pipeline candidates that will help it decrease its reliance on Keytruda. One of them is a potential influenza antiviral, CD388, that could help protect those at high risk of developing severe flu cases. Current flu vaccine options are not very effective, typically achieving efficacy levels of about 40% to 60%. As a result, many patients, especially the elderly and the immunocompromised, end up hospitalized. Merck is looking to fix that problem. The company's pipeline also features several in oncology and a potential weight-loss therapy.
Merck should succeed in navigating Keytruda's patent cliff and perform well long after. Meanwhile, it offers a forward yield of 3%, and it has increased its payouts by almost 94% over the past decade. Dividend seekers could be glad they bought this stock in 10 years.
Should you buy stock in Amgen right now?
Before you buy stock in Amgen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 8, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Merck. The Motley Fool has a disclosure policy.
2 Dividend Stocks to Double Up On Right Now was originally published by The Motley Fool
View Comments
- 2 Dividend Stocks to Double Up On Right Now
May 8, 2026 · fool.com
Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
May 7, 2026
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m. PT on Wednesday, May 13, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.
Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference-302766201.html
View Comments
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
May 7, 2026 · prnewswire.com
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.
